Rob van Maanen
Chief Tech/Sci/R&D Officer at BIOPHYTIS S.A.
Net worth: 171 $ as of 2024-04-29
Rob van Maanen active positions
Companies | Position | Start | End |
---|---|---|---|
BIOPHYTIS S.A. | Chief Tech/Sci/R&D Officer | 2021-09-08 | - |
Career history of Rob van Maanen
Former positions of Rob van Maanen
Companies | Position | Start | End |
---|---|---|---|
Astellas BV
Astellas BV Financial ConglomeratesFinance Part of Astellas Pharma, Inc., Astellas BV is a Dutch company that functions as an investment holding company. The company is based in Leiden, Netherlands. | Chief Tech/Sci/R&D Officer | - | - |
Khondrion BV
Khondrion BV Pharmaceuticals: MajorHealth Technology Khondrion BV is a Dutch clinical-stage biopharmaceutical company that focuses on discovering and developing therapies for mitochondrial diseases. The company is based in Nijmegen, Netherlands, and was founded in 2012 by Jan Smeitink, who has been the CEO since then. The company's lead drug candidate, sonlicromanol, is a first-in-class, oral small molecule that targets key underlying mechanisms of primary mitochondrial disease. The compound has been granted orphan drug designations for the treatment of various mitochondrial diseases. Khondrion collaborates with a clinical and academic network and patient organizations internationally to accelerate the discovery and development of its potential medicines. | Chief Tech/Sci/R&D Officer | - | - |
Training of Rob van Maanen
University of Utrecht | Doctorate Degree |
University of Amsterdam | Masters Business Admin |
Statistics
International
Netherlands | 5 |
France | 2 |
Operational
Chief Tech/Sci/R&D Officer | 3 |
Doctorate Degree | 1 |
Masters Business Admin | 1 |
Sectoral
Health Technology | 3 |
Consumer Services | 3 |
Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
BIOPHYTIS S.A. | Health Technology |
Private companies | 2 |
---|---|
Khondrion BV
Khondrion BV Pharmaceuticals: MajorHealth Technology Khondrion BV is a Dutch clinical-stage biopharmaceutical company that focuses on discovering and developing therapies for mitochondrial diseases. The company is based in Nijmegen, Netherlands, and was founded in 2012 by Jan Smeitink, who has been the CEO since then. The company's lead drug candidate, sonlicromanol, is a first-in-class, oral small molecule that targets key underlying mechanisms of primary mitochondrial disease. The compound has been granted orphan drug designations for the treatment of various mitochondrial diseases. Khondrion collaborates with a clinical and academic network and patient organizations internationally to accelerate the discovery and development of its potential medicines. | Health Technology |
Astellas BV
Astellas BV Financial ConglomeratesFinance Part of Astellas Pharma, Inc., Astellas BV is a Dutch company that functions as an investment holding company. The company is based in Leiden, Netherlands. | Finance |
- Stock Market
- Insiders
- Rob van Maanen
- Experience